Erenumab (INN; developmental code name AMG-334) is a human monoclonal antibody against the calcitonin gene-related peptide receptor (CGRPR) designed for the prevention of migraine.
This drug was developed by Amgen Inc.
In a Phase III clinical trial with 577 patients, the drug significantly reduced the number of migraine days per month by 3, versus 1.8 under placebo.
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Erenumab, American Medical Association.
- ↑ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
- 1 2 3 H. Spreitzer (24 October 2016). "Neue Wirkstoffe - Erenumab". Österreichische Apothekerzeitung (in German) (23/2016).